Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (D.K.S., D.A., B.P.); and Department of Chemistry, Washington State University, Pullman, Washington (D.R.D.).
Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (D.K.S., D.A., B.P.); and Department of Chemistry, Washington State University, Pullman, Washington (D.R.D.)
Drug Metab Dispos. 2024 Oct 16;52(11):1152-1160. doi: 10.1124/dmd.124.001477.
Protein abundance data of drug-metabolizing enzymes and transporters (DMETs) are useful for scaling in vitro and animal data to humans for accurate prediction and interpretation of drug clearance and toxicity. Targeted DMET proteomics that relies on synthetic stable isotope-labeled surrogate peptides as calibrators is routinely used for the quantification of selected proteins; however, the technique is limited to the quantification of a small number of proteins. Although the global proteomics-based total protein approach (TPA) is emerging as a better alternative for large-scale protein quantification, the conventional TPA does not consider differential sequence coverage by identifying unique peptides across proteins. Here, we optimized the TPA approach by correcting protein abundance data by the sequence coverage, which was applied to quantify 54 DMETs for characterization of 1) differential tissue DMET abundance in the human liver, kidney, and intestine, and 2) interindividual variability of DMET proteins in individual intestinal samples ( = 13). Uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), microsomal glutathione S-transferases (MGST1, MGST2, and MGST3) carboxylesterase 2 (CES2), and multidrug resistance-associated protein 2 (MRP2) were expressed in all three tissues, whereas, as expected, four cytochrome P450s (CYP3A4, CYP3A5, CYP2C9, and CYP4F2), UGT1A1, UGT2B17, CES1, flavin-containing monooxygenase 5, MRP3, and P-glycoprotein were present in the liver and intestine. The top three DMET proteins in individual tissues were: CES1>CYP2E1>UGT2B7 (liver), CES2>UGT2B17>CYP3A4 (intestine), and MGST1>UGT1A6>MGST2 (kidney). CYP3A4, CYP3A5, UGT2B17, CES2, and MGST2 showed high interindividual variability in the intestine. These data are relevant for enhancing in vitro to in vivo extrapolation of drug absorption and disposition and can be used to enhance the accuracy of physiologically based pharmacokinetic prediction of systemic and tissue concentration of drugs. SIGNIFICANCE STATEMENT: This study quantified the abundance and compositions of drug-metabolizing enzymes and transporters in pooled human liver, intestine, and kidney microsomes as well as individual intestinal microsomes using an optimized global proteomics approach. The data revealed large intertissue differences in the abundance of these proteins and high intestinal interindividual variability in the levels of cytochrome P450s (e.g., CYP3A4 and CYP3A5), uridine diphosphate-glucuronosyltransferase 2B17, carboxylesterase 2, and microsomal glutathione S-transferase 2. These data are applicable for the prediction of first-pass metabolism and tissue-specific drug clearance.
药物代谢酶和转运体(DMET)的蛋白质丰度数据可用于将体外和动物数据外推至人体,以准确预测和解释药物清除率和毒性。依赖于合成稳定同位素标记的替代肽作为校准物的靶向 DMET 蛋白质组学常用于对选定蛋白质进行定量;然而,该技术仅限于对少数蛋白质进行定量。尽管基于全局蛋白质组学的总蛋白方法(TPA)作为一种大规模蛋白质定量的更好替代方法正在出现,但传统的 TPA 在识别蛋白质中独特肽时没有考虑到差异的序列覆盖范围。在这里,我们通过序列覆盖来校正蛋白质丰度数据,从而优化了 TPA 方法,并应用于定量 54 种 DMET,以表征 1)人肝、肾和肠中 DMET 的差异组织丰度,以及 2)个体肠样本中 DMET 蛋白的个体间变异性(n = 13)。尿苷二磷酸-葡萄糖醛酸基转移酶 2B7(UGT2B7)、微粒体谷胱甘肽 S-转移酶 1(MGST1)、MGST2 和 MGST3、羧酸酯酶 2(CES2)和多药耐药相关蛋白 2(MRP2)在所有三种组织中均有表达,而正如预期的那样,四种细胞色素 P450(CYP3A4、CYP3A5、CYP2C9 和 CYP4F2)、UGT1A1、UGT2B17、CES1、黄素单加氧酶 5、MRP3 和 P-糖蛋白存在于肝脏和肠道中。个体组织中排名前三的 DMET 蛋白分别为:CES1>CYP2E1>UGT2B7(肝脏)、CES2>UGT2B17>CYP3A4(肠道)和 MGST1>UGT1A6>MGST2(肾脏)。CYP3A4、CYP3A5、UGT2B17、CES2 和 MGST2 在肠道中表现出高个体间变异性。这些数据对于增强药物吸收和处置的体外到体内外推具有重要意义,可用于提高基于生理学的药物系统和组织浓度的药代动力学预测的准确性。意义陈述:本研究使用优化的全局蛋白质组学方法,定量了人肝、肠和肾微粒体以及个体肠微粒体中药物代谢酶和转运体的丰度和组成。数据显示,这些蛋白质在组织间存在大量丰度差异,CYP3A4 和 CYP3A5、尿苷二磷酸-葡萄糖醛酸基转移酶 2B17、羧酸酯酶 2 和微粒体谷胱甘肽 S-转移酶 2 的水平在肠道中个体间存在高度变异性。这些数据适用于预测首过代谢和组织特异性药物清除率。